Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-...
Agreement to make Lunit INSIGHT MMG accessible to over 400 sites across France SEOUL, South Korea, ...
Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment out...
* Two new studies show Lunit INSIGHT MMG cuts radiologist workload by 50% in a double reading env...
* Lunit SCOPE IO® demonstrates potential to assess immune phenotype as an AI-powered biomarker fo...
* Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pa...
* AI-based tumor microenvironment classification utilizing Lunit SCOPE IO® shows promise for guid...
* Lancet Digital Health study highlights Lunit INSIGHT CXR as top performer in TB screening, show...
* Middle East's first full-scale AI adoption for national screening marks Lunit's latest mileston...
- Lunit's ASCO 2024 presentations to highlight advances including HER2 ultra-low detection and AI-p...
SEOUL, South Korea, May 22, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-po...
- From research to real-world impact: Lunit demonstrates Lunit INSIGHT's clinical safety, effective...
- Employing Lunit INSIGHT MMG, a Turkish study showcases 70% efficiency improvements, advancements ...
- Lunit's AACR 2024 presentations to spotlight HER2 mutation insights and CNTN4's role in immunothe...
- New research published in Clinical Cancer Research shows significant improvement in distant recur...
* New supply contract to bring Lunit INSIGHT CXR to TeleDiag in France and Lunit INSIGHT MMG to t...
- Lunit SCOPE HER2 and Lunit SCOPE ER/PR significantly improve pathologist concordance and accuracy...
- Volpara shareholder meeting to be held on April 12, 2024: Culminating the acquisition journey for...
- Lunit to unveil four oral presentations and three poster presentations at ECR 2024, highlighting ...
- A new study published in the Journal for ImmunoTherapy of Cancer (JITC) shows that Lunit's AI-po...
